Company name: Solyndra Some investors: selected VC investors. The total amount of financing disclosed by American venture capital partners is $6,543.8+$22 million. Suntech and First Solar are both industry giants, and it is difficult to make a profit. Therefore, it is difficult for small and radical solar companies to continue to operate.
Solyndra claims that it is evaluating its future options and may sell its business or CIGS technology.
Company Name: Jawbone Some venture capital investors: khosla Venture Capital, Sequoia and Peng Kaihua Ying. The total amount of financing disclosed was $929.9 million. 2065438+July 2007, Jawbone, an equipment manufacturer, became one of the most famous and failed startups in history.
Jawbone announced that it would sell its assets. Although $930 million has been invested in the "life cycle" of 17, Jawbone's market share in headphones, fitness trackers and wireless headphones is not large enough to make a living.
Looking back on history, Jawbone's failure can be said to be the "second most expensive" among failed venture-backed startups.
Enterprise name: VC investors about solar energy: technical partner, DCM Ventures, BP alternative energy venture capital. The total amount of financing disclosed is $665,438+$400 million. About solar energy manufacturing cadmium telluride thin film photovoltaic modules for solar panels.
During its operation, the company received support from scientific research institutions, such as Colorado State University and National Science Foundation. In addition to the support of VC investors, abundcy Solar also received loans from the US Department of Defense and financial support from the US Department of Energy. In 20 12, solar energy suffered a fiasco. At that time, the company had raised 60140,000 USD, and its failure was the "third most expensive" in our database.
Company name: ReVision Optics Some VC investors: InterWest Partners, Canaan Partners, Domain Associates and ProQuest Investments disclosed that the total financing amount was $654.38+$72 million. Corrective Optics has developed an implantable corneal device that can treat presbyopia.
John Kilcoyne, President and CEO of ReVision, said in an interview that hyperopia treatment is full of challenges. He explained that ReVision was closed mainly because the company could not make its business develop fast enough. If we want to turn cash flow from negative to positive, the company needs more funds, but investors are unwilling to pay the bill. In the business model of ophthalmologists, corneal inlays may find a place in the future, but at present, compared with refractive and cataract surgery, corneal inlays need time to practice and continue to work hard. After the operation is completed, the average patient will have to visit again. Kilcoin said, "Ophthalmologists don't want to see patients anymore."